Your Article Summary
See Latest ArticlesBioMimetic Therapeutics, Inc. Announces Completion of Rights Offering and Sale of Shares in Standby Purchase
BioMimetic Therapeutics, 06/26/09
BioMimetic Therapeutics, Inc. announced that it has closed its previously announced rights offering. The Company received valid subscriptions for all of shares purchasable in the rights offering, including shares subscribed for by certain of the Company's stockholders in the exercise of their over-subscription rights, at a subscription price of $8.50 per share. The Company issued the shares purchased in the rights offering to the purchasers on June 2009.
Today in Marketing/Media/ROI...keeping you current
Receive free subspecialty "5-minute updates" via email
Salix Receives FDA Marketing Approval for Metozolv
Salix Pharmaceuticals, 09/09/09
Nabi Biopharmaceuticals Completes Sale of PentaStaph to GlaxoSmithKline PLC
Nabi Biopharmaceuticals, 11/05/09
Shire Reports Tolerability and Clinical Effects Results of DAYTRANA from Study in Adolescents with ADHD
Shire, 11/02/09